Urinary tract obstruction and nephrostomy drainage in pelvic malignant disease.
OBJECTIVE
To determine the survival of patients after percutaneous nephrostomy drainage (PND) for obstructive uropathy secondary to pelvic malignant disease.


METHODS
The records of 77 patients undergoing PND for obstructive uropathy were reviewed. Patients were classified according to the nature of the obstructing lesion: Group I (primary untreated malignancy, 31 patients); Group II (recurrent malignancy with further treatment, 15 patients); Group III (recurrent malignancy with no further treatment, 12 patients); and Group IV (benign disease as a consequence of previous treatment, 19 patients). Outcome was assessed by survival over a mean follow-up of 20 months (range 2 days-8.3 years).


RESULTS
Overall median survival was 26 weeks, with a 5-year survival of 22%. The survival in Groups I and II was not significantly different (median survival 27 and 20 weeks, respectively; 5-year survival, 10% and 20%, respectively). Group III patients had a poor prognosis (median survival 6.5 weeks) with no patient surviving beyond one year, whilst Group IV patients fared best with a 5-year survival of 64%. The commonest primary tumour type was carcinoma of the cervix (42 patients), and these patients were analysed as a subset. Benign post-radiation fibrosis was found in 16 of 27 patients (59%). Survival was related to the diagnostic group.


CONCLUSIONS
The nature and extent of the obstructing lesion and its potential for further treatment are the major determinants of post-nephrostomy survival. Every effort should therefore be made to identify the nature of the obstruction before deciding on PND.
Lau
M W
MW
Department of Urology, Christie Hospital NHS Trust, Withington, Manchester, UK.
Temperley
D E
DE
Mehta
S
S
Johnson
R J
RJ
Barnard
R J
RJ
Clarke
N W
NW
D000328:Adult; D000368:Aged; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009403:Nephrostomy, Percutaneous; D010386:Pelvic Neoplasms / Q000150:complications*; D011379:Prognosis; D016019:Survival Analysis; D015996:Survival Rate; D014517:Ureteral Obstruction / Q000209:etiology / Q000601:surgery*; D002583:Uterine Cervical Neoplasms / Q000150:complications